Ferring Pharmaceuticals today announced three oral presentations and one poster presentation at Digestive Disease Week DDW 2023 for REBYOTA fecal microbiota live jslm a firstinclass singledose microbiomebased treatment approved by the U.S. Food and Drug Administration FDA for the prevention of recurrent C. difficile C. diff infection in individuals 18 years of age and older following antibiotic treatment for recurrent C. diff infection.
The treatment is the second live microbiota therapeutic approved by the FDA, coming just a few months after the agency approved RBX2660 for recurrent C. difficile infections.
Dr Paul Feuerstadt joins Dr David Hudesmand and Dr Jordan Axelrad in a discussion about treatment approaches for C difficile infections, and the latest advances in treating recurrent infections with fecal microbiota transplantation.
Dr Paul Feuerstadt joins Dr David Hudesmand and Dr Jordan Axelrad in a discussion about treatment approaches for C difficile infections, and the latest advances in treating recurrent infections with fecal microbiota transplantation.